HMW-MAA

Product List

Here we offer you a range of HMW-MAA CAR products. You can find the product you want by selecting the target species, antibody cloning, receptor construction, and more.

Background

The tumor-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4), also known as HMW-MAA, is a highly glycosylated transmembrane proteoglycan that is overexpressed in 67% GBM. Studies have shown that CSPG4 is overexpressed in a variety of solid tumors, including malignant melanoma, breast cancer subsets, mesothelioma, and neuroblastoma. In addition, CSPG4 expression was also found in some normal tissues. To date, CSPG4 is considered a promising target in targeted immunotherapy for cancer.

Fig.1 HMW-MAA is expressed on circulating melanoma cells.¹

Associated Diseases

Metastatic Melanoma

Melanoma

Breast Cancer

Mesothelioma

Neuroblastoma

Anti-HMW-MAA CAR-T Services

Anti-HMW-MAA CAR-T In Vitro Assays

Creative Biolabs provides a series of CD123 CAR-T efficacy evaluation platforms in vitro, including but not limited to CD123 CAR expression testing, CD123 CAR-T cytokine release assays, in vitro toxicity testing, etc.

Anti-HMW-MAA CAR-T Expression Test

Creative Biolabs has successfully developed a series of fluorescently labeled CAR target-related protein products with our advanced site-directed labeling technology platform, which can meet the different needs of HMW-MAA CAR-T positive rate detection in an all-round way with its own product advantages.

Fig.2 Optimized HMW-MAA-specific CAR expression levels in PBL.²

Anti-HMW-MAA CAR-T Cytokine Release Test

In CAR-T cell therapy, the levels of four key cytokines, IL-2, IFN-γ, IL-6, and IL-10, can be measured to determine whether Cytokine Release Syndrome (CRS) is induced and its severity. Creative Biolabs offers multiplex kits that can measure the levels of these four factors in HMW-MAA CAR-T cells, either separately or simultaneously.

Fig.3 Cytokine release levels of optimized HMW-MAA-specific CAR.²

Anti-HMW-MAA CAR-T Cell Proliferation Test

In addition to cytokine secretion ability, the proliferation ability of HMW-MAA CAR-T cells is also a very important efficacy evaluation index for CAR-T cell therapy. Creative Biolabs has extensive experience in the efficacy evaluation of cell-based drugs to meet your diverse testing requirements.

Fig.4 Proliferation test of optimized HMW-MAA-specific CARs.²

Anti-HMW-MAA CAR-T In Vivo Assays

Cell line-derived xenograft (CDX) models or patient-derived xenograft (PDX) models are common models for in vivo studies of CAR-T. In addition, homograft models and animal models of human immune system reconstitution are also commonly found in published CAR T-cell therapy papers. After the animal is constructed, the CAR-T cells are re-infused, and then the downstream evaluation experiment is carried out. In vivo functional assessment of anti-HMW-MAA CAR-T cells include:

• Tumor model establishment: including NSG, C-NKG, NOG, BRGSF, PBMC-HIS, etc.
• Evaluation index: tumor size, in vivo imaging detection, etc.
• Tumorization methods: tail vein injection metastasis model, intraperitoneal injection metastasis model, belt tumor model, etc.
• Toxicity detection: weight/hair changes, mortality/organ toxicity, etc.

In addition to the above methods, Creative Biolabs also provides histopathological tests, including immunohistochemistry or H&E staining, to reflect the pathological changes of CAR-T cells, tumor cells or organ tissues from different dimensions.

References

1. Kamińska, Paula.; et al. "Liquid biopsy in melanoma: significance in diagnostics, prediction and treatment monitoring." International journal of molecular sciences. (2021) 22,18 9714.
2. Burns, W.R.; et al. "A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas." Cancer research. 70,8 (2010): 3027-33.